Related references
Note: Only part of the references are listed.The metabolic landscape of RAS-driven cancers from biology to therapy
Suman Mukhopadhyay et al.
NATURE CANCER (2021)
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
Matthew J. LaMarche et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer
Hao Chen et al.
ONCOGENE (2020)
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas
Kristen S. Hill et al.
MOLECULAR CANCER RESEARCH (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors
Tamer A. Ahmed et al.
CELL REPORTS (2019)
Metabolic rewiring in mutant Kras lung cancer
Emma M. Kerr et al.
FEBS JOURNAL (2018)
Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
R. D. Kim et al.
BRITISH JOURNAL OF CANCER (2018)
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma
Ho Yeong Lim et al.
CLINICAL CANCER RESEARCH (2018)
PI3K inhibition to overcome endocrine resistance in breast cancer
Niamh M. Keegan et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Dietrich A. Ruess et al.
NATURE MEDICINE (2018)
An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer
Tamkin Ahmadzada et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition
Jonathan R. LaRochelle et al.
NATURE COMMUNICATIONS (2018)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen et al.
NATURE (2016)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer
Edward B. Garon
SEMINARS IN ONCOLOGY (2015)
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib
N. Elster et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
Jiabei He et al.
SCIENTIFIC REPORTS (2015)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 (PTPN11)
Wei Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies
Bing Yu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop
Nicola Aceto et al.
NATURE MEDICINE (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Protein tyrosine phosphatase SHP-2: A proto-oncogene product that promotes Ras activation
Takashi Matozaki et al.
CANCER SCIENCE (2009)
Large-Scale Structural Analysis of the Classical Human Protein Tyrosine Phosphatome
Alastair J. Barr et al.
CELL (2009)
Constitutively Active SHP2 Cooperates with HoxA10 Overexpression to Induce Acute Myeloid Leukemia
Hao Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Christine A. Pratilas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The tyrosine phosphatase Shp2 (PTPN11) in cancer
Gordon Chan et al.
CANCER AND METASTASIS REVIEWS (2008)
The role of Shp2 (PTPN11) in cancer
M. Golam Mohi et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
Ba/F3 cells and their use in kinase drug discovery
Markus Warmuth et al.
CURRENT OPINION IN ONCOLOGY (2007)
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies
YY Chen et al.
GENES CHROMOSOMES & CANCER (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease
CP Kratz et al.
BLOOD (2005)
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells
S Schubbert et al.
BLOOD (2005)
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
ML Loh et al.
BLOOD (2004)
Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia
M Bentires-Alj et al.
CANCER RESEARCH (2004)
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
M Tartaglia et al.
NATURE GENETICS (2003)
Receptor-specific regulation of phosphatidylinositol 3′-kinase activation by the protein tyrosine phosphatase Shp2
SQ Zhang et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
M Tartaglia et al.
NATURE GENETICS (2001)
Share Paper
